|
| Home : AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan |
|
Mar 26
2019 |
AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan |
|
NORTH CHICAGO, Ill., March 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor, for the... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-erythrodermic-psoriasis-and-psoriatic-arthritis-in-japan-300818288.htm |
| |
|
Related News
|
» UrVenue Acquired by Hospitality Management Solutions to Expand Software Products and Services for Hospitality Industry
» Clayfin Names Rajesh Narasimha as the New CEO
|
|
|
